company background image
EBS logo

Emergent BioSolutions NYSE:EBS Stock Report

Last Price

US$2.47

Market Cap

US$127.9m

7D

-11.8%

1Y

-69.4%

Updated

18 Mar, 2024

Data

Company Financials +

Emergent BioSolutions Inc.

NYSE:EBS Stock Report

Market Cap: US$127.9m

EBS Stock Overview

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States.

EBS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Emergent BioSolutions Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Emergent BioSolutions
Historical stock prices
Current Share PriceUS$2.47
52 Week HighUS$13.67
52 Week LowUS$1.42
Beta1.22
1 Month Change58.33%
3 Month Change1.23%
1 Year Change-69.39%
3 Year Change-97.40%
5 Year Change-94.96%
Change since IPO-78.89%

Recent News & Updates

New CEO Appointment A Clear Positive For Emergent BioSolutions

Feb 27

Recent updates

New CEO Appointment A Clear Positive For Emergent BioSolutions

Feb 27

Emergent BioSolutions: Q3 Numbers Leave Work To Be Done

Dec 18

Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow

Nov 23

Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial

Aug 23

Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)

Aug 14

Emergent BioSolutions: Making A Big Bet On Narcan

Jul 21

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Jun 22
An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued

Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Apr 05
Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?

Emergent Biosolutions Q4 2022 Earnings Preview

Feb 24

An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Feb 16
An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued

Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M

Feb 15

Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments

Dec 07

Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance

Nov 09

Emergent doses first participant in Phase 1 trial for Lassa virus vaccine

Sep 06

Emergent BioSolutions: Now Long Through Sale Of October Put Spreads

Aug 24

A Look At The Fair Value Of Emergent BioSolutions Inc. (NYSE:EBS)

Aug 13
A Look At The Fair Value Of Emergent BioSolutions Inc. (NYSE:EBS)

Additional 135M COVID-19 vaccine doses destroyed at Emergent BioSolutions Baltimore plant

Aug 12

Emergent BioSolutions misses on top and bottom lines as it swings to quarterly loss

Aug 01

Moderna 2.0: 3 Stocks To Play The Potential Monkeypox Pandemic

Jul 26

Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt

Jul 26
Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt

Kamada inks $11.4 M supply deal for chickenpox preventive antibody Varizig

Jul 06

Emergent BioSolutions: A Top Pick For The Monkeypox Outbreak

May 29

Emergent BioSolutions Inc. (NYSE:EBS) Shares Could Be 37% Below Their Intrinsic Value Estimate

May 12
Emergent BioSolutions Inc. (NYSE:EBS) Shares Could Be 37% Below Their Intrinsic Value Estimate

Emergent BioSolutions (NYSE:EBS) Has A Pretty Healthy Balance Sheet

Apr 24
Emergent BioSolutions (NYSE:EBS) Has A Pretty Healthy Balance Sheet

Shareholder Returns

EBSUS BiotechsUS Market
7D-11.8%-2.1%-0.1%
1Y-69.4%10.4%28.4%

Return vs Industry: EBS underperformed the US Biotechs industry which returned 10.4% over the past year.

Return vs Market: EBS underperformed the US Market which returned 28.4% over the past year.

Price Volatility

Is EBS's price volatile compared to industry and market?
EBS volatility
EBS Average Weekly Movement26.7%
Biotechs Industry Average Movement11.9%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: EBS's share price has been volatile over the past 3 months.

Volatility Over Time: EBS's weekly volatility has increased from 17% to 27% over the past year.

About the Company

FoundedEmployeesCEOWebsite
19981,600Joe Papahttps://www.emergentbiosolutions.com

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector.

Emergent BioSolutions Inc. Fundamentals Summary

How do Emergent BioSolutions's earnings and revenue compare to its market cap?
EBS fundamental statistics
Market capUS$127.90m
Earnings (TTM)-US$760.50m
Revenue (TTM)US$1.05b

0.1x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EBS income statement (TTM)
RevenueUS$1.05b
Cost of RevenueUS$807.10m
Gross ProfitUS$242.20m
Other ExpensesUS$1.00b
Earnings-US$760.50m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-14.57
Gross Margin23.08%
Net Profit Margin-72.48%
Debt/Equity Ratio132.5%

How did EBS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.